GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MIL:1INCY) » Definitions » Pre-Tax Income

Incyte (MIL:1INCY) Pre-Tax Income : €245 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Incyte Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Incyte's pretax income for the three months ended in Sep. 2024 was €141 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was €245 Mil. Incyte's pretax margin was 13.76%.

During the past 13 years, Incyte's highest Pretax Margin was 22.57%. The lowest was -20.33%. And the median was 7.92%.


Incyte Pre-Tax Income Historical Data

The historical data trend for Incyte's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Pre-Tax Income Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 438.11 -190.88 504.84 499.49 764.98

Incyte Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.07 248.47 217.27 -362.10 141.03

Competitive Comparison of Incyte's Pre-Tax Income

For the Biotechnology subindustry, Incyte's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Incyte's Pre-Tax Income falls into.



Incyte Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Incyte's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=595.784+13.472+-2.339+158.043+0.0150000000001
=765

Incyte's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=152.717+-32.789+-0.697+21.8+-0.0030000000000143
=141

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €245 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte  (MIL:1INCY) Pre-Tax Income Explanation

Incyte's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=141.028/1025.222
=13.76%

During the past 13 years, Incyte's highest Pretax Margin was 22.57%. The lowest was -20.33%. And the median was 7.92%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Incyte's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines